Loading…

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment

RA is known to be associated with an increased risk of serious infection. Even more than 50 years ago, observational studies showed a greater than 2-fold increased risk of serious infection in RA. This was reinforced by various subsequent cohort studies. The elevated susceptibility of patients with...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2013-01, Vol.52 (1), p.53-61
Main Authors: Listing, Joachim, Gerhold, Kerstin, Zink, Angela
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c305t-a5791d91a3e484a9fdbcd7c5d557b6822e3bba8fe3bf09641870898d51e158353
cites cdi_FETCH-LOGICAL-c305t-a5791d91a3e484a9fdbcd7c5d557b6822e3bba8fe3bf09641870898d51e158353
container_end_page 61
container_issue 1
container_start_page 53
container_title Rheumatology (Oxford, England)
container_volume 52
creator Listing, Joachim
Gerhold, Kerstin
Zink, Angela
description RA is known to be associated with an increased risk of serious infection. Even more than 50 years ago, observational studies showed a greater than 2-fold increased risk of serious infection in RA. This was reinforced by various subsequent cohort studies. The elevated susceptibility of patients with RA can be explained by the pathobiology of the disease itself, the impact of chronic comorbid conditions, as well as sequelae of immunosuppressive treatment. It has been suggested that premature ageing of the immune system in RA contributes to weakened protection against infectious organisms. In addition, chronic comorbid conditions such as diabetes or chronic lung or kidney disease, disease-related functional disability, as well as lifestyle factors such as smoking, increase the risk in individual patients. For a long time glucocorticoids (GCs) have been used as potent immunosuppressive drugs in RA. There is evidence that they increase the risk of serious infections up to 4-fold in a dose-dependent manner. TNF-α inhibitors increase the serious infection risk up to 2-fold. They have, however, the potential to outweigh their risk when higher GC doses can be tapered down. If patients need higher dosages of GCs in addition to treatment with biologic agents, their risk of infection is substantial. This combination should be used carefully and, if possible, avoided in patients with additional risk factors such as older age or comorbid conditions.
doi_str_mv 10.1093/rheumatology/kes305
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1239055393</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1239055393</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-a5791d91a3e484a9fdbcd7c5d557b6822e3bba8fe3bf09641870898d51e158353</originalsourceid><addsrcrecordid>eNpNkEtPwzAQhC0EolD4BUjIRw6U-hE38RFVvKRKXMrZcuwNMU3iYjtC_fcEpa04zUo7s7P6ELqh5IESyeehhr7VyTf-czffQOREnKALmi3YjHDOTo8zyyboMsYvQoigvDhHE8apZJLSC6TWNeDg4gb7CruuApOc7yLWMXrjdAKLf1yq8aHMWaxDqoNLLt6PK5ciNr71oXTWpR3WncUpgE4tdOkKnVW6iXC91yn6eH5aL19nq_eXt-XjamaGt9NMi1xSK6nmkBWZlpUtjc2NsELk5aJgDHhZ6qIapCJykdEiJ4UsrKBARcEFn6K78e42-O8eYlKtiwaaRnfg-6go45IIwSUfrHy0muBjDFCpbXCtDjtFifojq_6TVSPZIXW7L-jLFuwxc0DJfwFzCXsG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1239055393</pqid></control><display><type>article</type><title>The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Listing, Joachim ; Gerhold, Kerstin ; Zink, Angela</creator><creatorcontrib>Listing, Joachim ; Gerhold, Kerstin ; Zink, Angela</creatorcontrib><description>RA is known to be associated with an increased risk of serious infection. Even more than 50 years ago, observational studies showed a greater than 2-fold increased risk of serious infection in RA. This was reinforced by various subsequent cohort studies. The elevated susceptibility of patients with RA can be explained by the pathobiology of the disease itself, the impact of chronic comorbid conditions, as well as sequelae of immunosuppressive treatment. It has been suggested that premature ageing of the immune system in RA contributes to weakened protection against infectious organisms. In addition, chronic comorbid conditions such as diabetes or chronic lung or kidney disease, disease-related functional disability, as well as lifestyle factors such as smoking, increase the risk in individual patients. For a long time glucocorticoids (GCs) have been used as potent immunosuppressive drugs in RA. There is evidence that they increase the risk of serious infections up to 4-fold in a dose-dependent manner. TNF-α inhibitors increase the serious infection risk up to 2-fold. They have, however, the potential to outweigh their risk when higher GC doses can be tapered down. If patients need higher dosages of GCs in addition to treatment with biologic agents, their risk of infection is substantial. This combination should be used carefully and, if possible, avoided in patients with additional risk factors such as older age or comorbid conditions.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/kes305</identifier><identifier>PMID: 23192911</identifier><language>eng</language><publisher>England</publisher><subject>Age Factors ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - complications ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - epidemiology ; Humans ; Infection - complications ; Infection - epidemiology ; Risk ; Smoking</subject><ispartof>Rheumatology (Oxford, England), 2013-01, Vol.52 (1), p.53-61</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c305t-a5791d91a3e484a9fdbcd7c5d557b6822e3bba8fe3bf09641870898d51e158353</citedby><cites>FETCH-LOGICAL-c305t-a5791d91a3e484a9fdbcd7c5d557b6822e3bba8fe3bf09641870898d51e158353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23192911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Listing, Joachim</creatorcontrib><creatorcontrib>Gerhold, Kerstin</creatorcontrib><creatorcontrib>Zink, Angela</creatorcontrib><title>The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>RA is known to be associated with an increased risk of serious infection. Even more than 50 years ago, observational studies showed a greater than 2-fold increased risk of serious infection in RA. This was reinforced by various subsequent cohort studies. The elevated susceptibility of patients with RA can be explained by the pathobiology of the disease itself, the impact of chronic comorbid conditions, as well as sequelae of immunosuppressive treatment. It has been suggested that premature ageing of the immune system in RA contributes to weakened protection against infectious organisms. In addition, chronic comorbid conditions such as diabetes or chronic lung or kidney disease, disease-related functional disability, as well as lifestyle factors such as smoking, increase the risk in individual patients. For a long time glucocorticoids (GCs) have been used as potent immunosuppressive drugs in RA. There is evidence that they increase the risk of serious infections up to 4-fold in a dose-dependent manner. TNF-α inhibitors increase the serious infection risk up to 2-fold. They have, however, the potential to outweigh their risk when higher GC doses can be tapered down. If patients need higher dosages of GCs in addition to treatment with biologic agents, their risk of infection is substantial. This combination should be used carefully and, if possible, avoided in patients with additional risk factors such as older age or comorbid conditions.</description><subject>Age Factors</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - epidemiology</subject><subject>Humans</subject><subject>Infection - complications</subject><subject>Infection - epidemiology</subject><subject>Risk</subject><subject>Smoking</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpNkEtPwzAQhC0EolD4BUjIRw6U-hE38RFVvKRKXMrZcuwNMU3iYjtC_fcEpa04zUo7s7P6ELqh5IESyeehhr7VyTf-czffQOREnKALmi3YjHDOTo8zyyboMsYvQoigvDhHE8apZJLSC6TWNeDg4gb7CruuApOc7yLWMXrjdAKLf1yq8aHMWaxDqoNLLt6PK5ciNr71oXTWpR3WncUpgE4tdOkKnVW6iXC91yn6eH5aL19nq_eXt-XjamaGt9NMi1xSK6nmkBWZlpUtjc2NsELk5aJgDHhZ6qIapCJykdEiJ4UsrKBARcEFn6K78e42-O8eYlKtiwaaRnfg-6go45IIwSUfrHy0muBjDFCpbXCtDjtFifojq_6TVSPZIXW7L-jLFuwxc0DJfwFzCXsG</recordid><startdate>201301</startdate><enddate>201301</enddate><creator>Listing, Joachim</creator><creator>Gerhold, Kerstin</creator><creator>Zink, Angela</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201301</creationdate><title>The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment</title><author>Listing, Joachim ; Gerhold, Kerstin ; Zink, Angela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-a5791d91a3e484a9fdbcd7c5d557b6822e3bba8fe3bf09641870898d51e158353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Age Factors</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - epidemiology</topic><topic>Humans</topic><topic>Infection - complications</topic><topic>Infection - epidemiology</topic><topic>Risk</topic><topic>Smoking</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Listing, Joachim</creatorcontrib><creatorcontrib>Gerhold, Kerstin</creatorcontrib><creatorcontrib>Zink, Angela</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Listing, Joachim</au><au>Gerhold, Kerstin</au><au>Zink, Angela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2013-01</date><risdate>2013</risdate><volume>52</volume><issue>1</issue><spage>53</spage><epage>61</epage><pages>53-61</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>RA is known to be associated with an increased risk of serious infection. Even more than 50 years ago, observational studies showed a greater than 2-fold increased risk of serious infection in RA. This was reinforced by various subsequent cohort studies. The elevated susceptibility of patients with RA can be explained by the pathobiology of the disease itself, the impact of chronic comorbid conditions, as well as sequelae of immunosuppressive treatment. It has been suggested that premature ageing of the immune system in RA contributes to weakened protection against infectious organisms. In addition, chronic comorbid conditions such as diabetes or chronic lung or kidney disease, disease-related functional disability, as well as lifestyle factors such as smoking, increase the risk in individual patients. For a long time glucocorticoids (GCs) have been used as potent immunosuppressive drugs in RA. There is evidence that they increase the risk of serious infections up to 4-fold in a dose-dependent manner. TNF-α inhibitors increase the serious infection risk up to 2-fold. They have, however, the potential to outweigh their risk when higher GC doses can be tapered down. If patients need higher dosages of GCs in addition to treatment with biologic agents, their risk of infection is substantial. This combination should be used carefully and, if possible, avoided in patients with additional risk factors such as older age or comorbid conditions.</abstract><cop>England</cop><pmid>23192911</pmid><doi>10.1093/rheumatology/kes305</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1462-0324
ispartof Rheumatology (Oxford, England), 2013-01, Vol.52 (1), p.53-61
issn 1462-0324
1462-0332
language eng
recordid cdi_proquest_miscellaneous_1239055393
source Oxford Journals Online; Alma/SFX Local Collection
subjects Age Factors
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - epidemiology
Humans
Infection - complications
Infection - epidemiology
Risk
Smoking
title The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T05%3A48%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20risk%20of%20infections%20associated%20with%20rheumatoid%20arthritis,%20with%20its%20comorbidity%20and%20treatment&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Listing,%20Joachim&rft.date=2013-01&rft.volume=52&rft.issue=1&rft.spage=53&rft.epage=61&rft.pages=53-61&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/kes305&rft_dat=%3Cproquest_cross%3E1239055393%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c305t-a5791d91a3e484a9fdbcd7c5d557b6822e3bba8fe3bf09641870898d51e158353%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1239055393&rft_id=info:pmid/23192911&rfr_iscdi=true